stoxline Quote Chart Rank Option Currency Glossary
  
Eterna Therapeutics Inc. (ERNA)
2.15  0 (0%)    04-19 16:00
Open: 2.05
High: 2.1505
Volume: 3,735
  
Pre. Close: 2.15
Low: 2.05
Market Cap: 12(M)
Technical analysis
2024-04-19 5:09:12 PM
Short term     
Mid term     
Targets 6-month :  2.71 1-year :  2.92
Resists First :  2.32 Second :  2.5
Pivot price 2.22
Supports First :  2.02 Second :  1.68
MAs MA(5) :  2.15 MA(20) :  2.25
MA(100) :  1.8 MA(250) :  2.06
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  20.4 D(3) :  16.4
RSI RSI(14): 48.1
52-week High :  3.45 Low :  0.83
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ ERNA ] has closed above bottom band by 20.8%. Bollinger Bands are 55.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 15 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.16 - 2.17 2.17 - 2.17
Low: 2.02 - 2.04 2.04 - 2.05
Close: 2.13 - 2.15 2.15 - 2.17
Company Description

Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.

Headline News

Tue, 16 Apr 2024
Eterna Therapeutics Inc. (NASDAQ:ERNA) Shares Bought by Vanguard Group Inc. - Defense World

Fri, 15 Mar 2024
ERNA Stock Earnings: Eterna Therapeutics Reported Results for Q4 2023 - InvestorPlace

Sun, 03 Mar 2024
ERNA Stock Quote Price and Forecast - CNN

Tue, 20 Feb 2024
Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors - GlobeNewswire

Wed, 20 Dec 2023
Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer - Yahoo Finance

Thu, 14 Dec 2023
Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 5 (M)
Held by Insiders 2.95e+006 (%)
Held by Institutions 39.3 (%)
Shares Short 38 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -2.059e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -33 %
Return on Assets (ttm) 911.7 %
Return on Equity (ttm) -36.2 %
Qtrly Rev. Growth 68000 %
Gross Profit (p.s.) 0
Sales Per Share -37.04
EBITDA (p.s.) 0
Qtrly Earnings Growth -4.1 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -20 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.06
Price to Cash Flow 42.79
Stock Dividends
Dividend 0
Forward Dividend 42430
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android